SLC25A5 and breast carcinoma: Therefore, to evaluate whether ANT2 suppression increases the TRAIL sensitivity of breast cancer cells, we treated the TRAIL-resistant MCF7 cells with recombinant human TRAIL (100 ng/ml) after transfecting then with ANT2 shRNA.